Role of Pemetrexed in Sdvanced Non-Small-Cell Lung Cancer: Meta-Analysis of Randomized Controlled Trials, with Histology Subgroup Analysis
Pourquoi ce travail est-il dans la base ?
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Le tri à trois modèles
les 1 000 travaux triés →Les trois modèles l'ont jugé hors champ.
Meta-analysis of randomized trials of pemetrexed in non-small-cell lung cancer; a synthesis method used to answer a clinical question, the paradigm OUT case in the rubric.
The meta-analysis answers a clinical treatment question rather than studying how meta-analyses are done.
Clinical meta-analysis of pemetrexed for lung cancer; method used to answer a treatment question.
Résumé
PURPOSE: Platinum-based regimens represent the standard first-line treatment for non-small-cell lung cancer (nsclc). However, newer data have established a role for pemetrexed in the treatment of this disease. Such data suggest that histology represents a determining factor in the selection of treatment. METHODS: We undertook a systematic review of the literature for randomized controlled trials that compared the efficacy of pemetrexed with that of other treatments in advanced nsclc. Data and study quality were assessed according to published guidelines. RESULTS: We identified five trials that compared pemetrexed with other treatments or with placebo. Overall survival for patients treated with pemetrexed was superior to that with other treatments: hazard ratio (hr): 0.89; 95% confidence interval (ci): 0.80 to 0.99. The survival benefit was limited to patients with non-squamous histology: hr: 0.82; 95% ci: 0.73 to 0.91. Pemetrexed was inferior to other chemotherapy options in patients with squamous histology: hr: 1.19; 95% ci: 0.99 to 1.43. CONCLUSIONS: Compared with other chemotherapy agents, pemetrexed is more effective for the treatment of nsclc in patients with non-squamous histology.
Conservé avec la notice de tri, où il sert de preuve aux étiquettes ci-dessus.
La notice
- Revue
- Current Oncology
- Thématique
- Lung Cancer Treatments and Mutations
- Domaine
- Medicine
- Établissements canadiens
- McMaster UniversityJuravinski Cancer CentreCredit Valley Hospital
- Organismes subventionnaires
- —
- Mots-clés
- PemetrexedMedicineInternal medicineLung cancerHazard ratioOncologyChemotherapyHistologyRandomized controlled trialPlaceboConfidence intervalPathologyCisplatin
- Résumé présent dans OpenAlex
- oui